miR-619-5p and cardiogenic shock in patients with ST-segment elevation myocardial infarction.
cardiovascular disease
epigenetic
inflammatory response
mortality risk
plasma miRNAs
Journal
European journal of clinical investigation
ISSN: 1365-2362
Titre abrégé: Eur J Clin Invest
Pays: England
ID NLM: 0245331
Informations de publication
Date de publication:
20 Feb 2024
20 Feb 2024
Historique:
revised:
12
02
2024
received:
14
12
2023
accepted:
13
02
2024
medline:
20
2
2024
pubmed:
20
2
2024
entrez:
20
2
2024
Statut:
aheadofprint
Résumé
Cardiogenic shock (CS) is a severe myocardial dysfunction secondary to various cardiac conditions including ST-segment elevation acute myocardial infarction (STEMI) and associated with a high risk of death. Little is known on epigenetic determinants in CS. Here, we investigated plasma miRNAs in relation to CS stratification in STEMI-patients. STEMI-patients (n = 49), with (CS, n = 25) and without CS (non-CS, n = 24) fulfilling inclusion criteria were included from HSCSP-cohort (Derivation-cohort). CS-miRNAs were analysed by Affymetrix-microarray and RT-PCR. Results were validated in a second cohort of CS-patients (CardShock: n = 35) with similar inclusion/exclusion criteria as the derivation cohort. In silico analysis were performed to identify potential miRNA target genes. Of the 5-miRNA signature obtained from microarray analysis, miR-619-5p showed higher levels in CS than in Non-CS patients (p = .003) and discriminating power for CS by ROC (AUC: .752, p = .003). miR-619-5p directly associated with risk scores [GRACE, p = .001; CardShock, p < .001]. Furthermore, miR-619-5p showed discrimination power for death in CS. Thus, miRNA levels were significantly higher in patients with mortality outcome both in the Derivation HSCSP-cohort (p = .02; AUC: .78 ± .095) and the Validation CardShock-cohort (p = .017; AUC: .737 ± .086) By in silico analysis, miR-619-5p target genes and TNF-alpha were involved in the regulation of inflammation. miR-619-5p and TNF-alpha levels discriminated mortality outcome in CS-patients during 30-day follow-up (Validation-Cohort: ROC: .812, p = .002; HR: 9.99, p = .003). Up-regulation of miR-619-5p is found in the plasma of STEMI-patients with CS and mortality outcome. These findings highlight the specificity of epigenetic regulation of inflammation on the disease severity of MI.
Sections du résumé
BACKGROUND
BACKGROUND
Cardiogenic shock (CS) is a severe myocardial dysfunction secondary to various cardiac conditions including ST-segment elevation acute myocardial infarction (STEMI) and associated with a high risk of death. Little is known on epigenetic determinants in CS. Here, we investigated plasma miRNAs in relation to CS stratification in STEMI-patients.
METHODS
METHODS
STEMI-patients (n = 49), with (CS, n = 25) and without CS (non-CS, n = 24) fulfilling inclusion criteria were included from HSCSP-cohort (Derivation-cohort). CS-miRNAs were analysed by Affymetrix-microarray and RT-PCR. Results were validated in a second cohort of CS-patients (CardShock: n = 35) with similar inclusion/exclusion criteria as the derivation cohort. In silico analysis were performed to identify potential miRNA target genes.
RESULTS
RESULTS
Of the 5-miRNA signature obtained from microarray analysis, miR-619-5p showed higher levels in CS than in Non-CS patients (p = .003) and discriminating power for CS by ROC (AUC: .752, p = .003). miR-619-5p directly associated with risk scores [GRACE, p = .001; CardShock, p < .001]. Furthermore, miR-619-5p showed discrimination power for death in CS. Thus, miRNA levels were significantly higher in patients with mortality outcome both in the Derivation HSCSP-cohort (p = .02; AUC: .78 ± .095) and the Validation CardShock-cohort (p = .017; AUC: .737 ± .086) By in silico analysis, miR-619-5p target genes and TNF-alpha were involved in the regulation of inflammation. miR-619-5p and TNF-alpha levels discriminated mortality outcome in CS-patients during 30-day follow-up (Validation-Cohort: ROC: .812, p = .002; HR: 9.99, p = .003).
CONCLUSIONS
CONCLUSIONS
Up-regulation of miR-619-5p is found in the plasma of STEMI-patients with CS and mortality outcome. These findings highlight the specificity of epigenetic regulation of inflammation on the disease severity of MI.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e14186Subventions
Organisme : Agencia Estatal de Investigación
ID : 10.13039/501100011033-[PID2019-107160RB-I00]
Organisme : Instituto de Salud Carlos III
ID : PI22/01930
Organisme : Instituto de Salud Carlos III
ID : Red RICORS TERAV- RD21/0017/0013
Organisme : Spanish Society of Cardiology (SEC)
ID : Investigación Clínica (2015)
Informations de copyright
© 2024 Stichting European Society for Clinical Investigation Journal Foundation. Published by John Wiley & Sons Ltd.
Références
Tehrani BN, Truesdell AG, Sherwood MW, et al. Standardized team-based care for cardiogenic shock. J Am Coll Cardiol. 2019;73(13):1659-1669.
Van Diepen S, Katz JN, Albert NM, et al. Contemporary management of cardiogenic shock: a scientific statement from the American Heart Association. Circulation. 2017;136(16):e232-e268.
Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of. Eur Heart J. 2016;37(27):2129-2200.
Thiele H, Ohman EM, de Waha-Thiele S, Zeymer U, Desch S. Management of cardiogenic shock complicating myocardial infarction: an update 2019. Eur Heart J. 2019;40(32):2671-2683.
Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116(2):281-297.
Wang Y, Pan X, Fan Y, et al. Dysregulated expression of microRNAs and mRNAs in myocardial infarction. Am J Transl Res. 2015;7(11):2291-2304.
Velle-Forbord T, Eidlaug M, Debik J, et al. Circulating microRNAs as predictive biomarkers of myocardial infarction: evidence from the HUNT study. Atherosclerosis. 2019;289:1-7.
Kumar D, Narang R, Sreenivas V, et al. Circulatory miR-133b and miR-21 as novel biomarkers in early prediction and diagnosis of coronary artery disease. Genes (Basel). 2020;11(2):164.
Harjola VP, Lassus J, Sionis A, et al. Clinical picture and risk prediction of short-term mortality in cardiogenic shock. Eur J Heart Fail. 2015;17(5):501-509.
Jäntti T, Segersvärd H, Tolppanen H, et al. Circulating levels of microRNA 423-5p are associated with 90 day mortality in cardiogenic shock. ESC Heart Fail. 2019;6(1):98-102.
Gilje P, Frydland M, Bro-Jeppesen J, et al. The association between plasma miR-122-5p release pattern at admission and all-cause mortality or shock after out-of-hospital cardiac arrest. Biomarkers. 2019;24(1):29-35.
Hänninen M, Jäntti T, Tolppanen H, et al. Association of miR-21-5p, miR-122-5p, and miR-320a-3p with 90-day mortality in cardiogenic shock. Int J Mol Sci. 2020;21(21):1-12.
Fox KAA, FitzGerald G, Puymirat E, et al. Should patients with acute coronary disease be stratified for management according to their risk? Derivation, external validation and outcomes using the updated GRACE risk score. BMJ Open. 2014;4(2):e004425.
Pöss J, Köster J, Fuernau G, et al. Risk stratification for patients in cardiogenic shock after acute myocardial infarction. J Am Coll Cardiol. 2017;69(15):1913-1920.
Ward JA, Esa N, Pidikiti R, et al. Circulating cell and plasma microRNA profiles differ between non-STSegment and ST-segment-elevation myocardial infarction. Fam Med Med Sci Res. 2013;02(2):108.
Bai R, Yang Q, Xi R, Li L, Shi D, Chen K. miR-941 as a promising biomarker for acute coronary syndrome. BMC Cardiovasc Disord. 2017;17(1):227.
O'Sullivan JF, Neylon A, McGorrian C, Blake GJ. miRNA-93-5p and other miRNAs as predictors of coronary artery disease and STEMI. Int J Cardiol. 2016;224:310-316.
Xiao S, Xue T, Pan Q, et al. MicroRNA-146a serves as a biomarker for adverse prognosis of ST-segment elevation myocardial infarction. Cardiovasc Ther. 2021;2021:2923441.
Escate R, Padró T, Suades R, et al. High miR-133a levels in the circulation anticipates presentation of clinical events in familial hypercholesterolaemia patients. Cardiovasc Res. 2021;117(1):109-122.
Wang X, Tian L, Sun Q. Diagnostic and prognostic value of circulating miRNA-499 and miRNA-22 in acute myocardial infarction. J Clin Lab Anal. 2020;34(8):2410-2417.
Kim DH, Park S, Kim HR, et al. Tumor-derived exosomal miR-619-5p promotes tumor angiogenesis and metastasis through the inhibition of RCAN1.4. Cancer Lett. 2020;475:2-13.
Knyazev EN, Fomicheva KA, Mikhailenko DS, et al. Plasma levels of hsa-miR-619-5p and hsa-miR-1184 differ in prostatic benign hyperplasia and cancer. Bull Exp Biol Med. 2016;161(1):108-111.
Shkurnikov MY, Makarova YA, Knyazev EN, et al. Plasma level of hsa-miR-619-5p microRNA is associated with prostatic cancer dissemination beyond the capsule. Bull Exp Biol Med. 2017;163(4):475-477.
Feng L, Feng Z, Hu J, et al. Identification of hsa-miR-619-5p and hsa-miR-4454 in plasma-derived exosomes as a potential biomarker for lung adenocarcinoma. Front Genet. 2023;14:1138230.
Liu C, Lai Y, Ying S, Zhan J, Shen Y. Plasma exosome-derived microRNAs expression profiling and bioinformatics analysis under cross-talk between increased low-density lipoprotein cholesterol level and ATP-sensitive potassium channels variant rs1799858. J Transl Med. 2020;18(1):459.
Ørn S, Ueland T, Manhenke C, et al. Increased interleukin-1β levels are associated with left ventricular hypertrophy and remodelling following acute ST segment elevation myocardial infarction treated by primary percutaneous coronary intervention. J Intern Med. 2012;272(3):267-276.
Kristono GA, Holley AS, Hally KE, et al. An IL-6-IL-8 score derived from principal component analysis is predictive of adverse outcome in acute myocardial infarction. Cytokine X. 2020;2(4):100037.
Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377(12):1119-1131.
Guo J, Hu Z, Ren L, et al. Circulating tumor necrosis factor-α, interleukin-1β, and interleukin-17A estimates increased major adverse cardiac event risk in acute myocardial infarction patients. J Clin Lab Anal. 2023;37(5):e24853.
Sionis A, Suades R, Sans-Roselló J, et al. Circulating microparticles are associated with clinical severity of persistent ST-segment elevation myocardial infarction complicated with cardiogenic shock. Int J Cardiol. 2018;258:249-256.